Washington (Reuters) – Astrazeneca announced on Monday that it planned to invest $ 50 billion to increase its production and research capacities in the United States by 2030, imitating other pharmaceutical companies that have announced investments in the country after Donald Trump threatened to impose important customs duties against the sector.
In a press release, Astrazeneca said this investment would finance a new drug production center in the State of Virginia and expand research and development centers located in Maryland, Massachusetts, California, Indiana and Texas.
The Anglo-Swedish group said that this approach was aims to reach an annual turnover of $ 80 billion by 2030, half of which was made in the United States.
The group’s general manager, Pascal Soriot, made these announcements from Washington.
In 2024, Astrazeneca achieved more than 40% of its global turnover in the United States, the main global pharmaceutical market, which the group erected priority even before Donald Trump returns to the American presidency last January.
Donald Trump has overlooked Washington’s commercial policy, deciding on customs duties against specific sectors and dozens of trade partners in the United States. He repeated his intention to strongly tax the pharmaceutical sector, with the aim of pushing more production in the country.
Before Astrazeneca, other companies in the sector have announced significant investments in the United States, such as the Swiss Roche group, which said in April that it intended to invest $ 50 billion, or Johnson & Johnson, Novartis and Sanofi.
(Maggie Fick and Ahmed Aboulenein; Jean Terzian)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
